-
2
-
-
0030969826
-
Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study
-
Khosla S., Atkinson E.J., Melton L.J., et al. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study. J Clin Endocrinol Metab 1997, 82(5):1522-1527.
-
(1997)
J Clin Endocrinol Metab
, vol.82
, Issue.5
, pp. 1522-1527
-
-
Khosla, S.1
Atkinson, E.J.2
Melton, L.J.3
-
3
-
-
84940086823
-
-
Accessed December 9, 2014.
-
International Society for Clinical Densitometry Official Positions - Adult. 2013. Available at: . Accessed December 9, 2014. http://www.iscd.org/official-positions/2013-iscd-official-positions-adult.
-
(2013)
-
-
-
4
-
-
0028060362
-
The diagnosis of osteoporosis
-
Kanis J.A., Melton L.J., Christiansen C., et al. The diagnosis of osteoporosis. J Bone Miner Res 1994, 9(8):1137-1141.
-
(1994)
J Bone Miner Res
, vol.9
, Issue.8
, pp. 1137-1141
-
-
Kanis, J.A.1
Melton, L.J.2
Christiansen, C.3
-
5
-
-
21244471020
-
Assessment of fracture risk
-
Kanis J.A., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos Int 2005, 16(6):581-589.
-
(2005)
Osteoporos Int
, vol.16
, Issue.6
, pp. 581-589
-
-
Kanis, J.A.1
Borgstrom, F.2
De Laet, C.3
-
6
-
-
84940086824
-
-
Accessed December 9, 2014.
-
US Preventive Services Task Force. Screening for osteoporosis recommendation statement. 2011. Available at: . Accessed December 9, 2014. http://www.uspreventiveservicestaskforce.org/uspstf10/osteoporosis/osteors.htm.
-
(2011)
-
-
-
7
-
-
84940086825
-
-
Accessed December 9, 2014.
-
National Ostoporosis Foundation. 2013 Clinician's guide to prevention and treatment of osteoporosis. Available at: . Accessed December 9, 2014. http://nof/public/content/resource/913/files/580.pdf.
-
-
-
-
8
-
-
80052725039
-
-
Institute of Medicine, Washington, DC, Available at:, Accessed December 9, 2014
-
Ross C.A., Taylor C.L., Yaktine A.L., et al. IOM report on calcium and vitamin D 2010, Institute of Medicine, Washington, DC, Available at:, Accessed December 9, 2014. http://www.iom.edu/vitaminD.
-
(2010)
IOM report on calcium and vitamin D
-
-
Ross, C.A.1
Taylor, C.L.2
Yaktine, A.L.3
-
9
-
-
6344250905
-
Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah
-
Wengreen H.J., Munger R.G., West N.A., et al. Dietary protein intake and risk of osteoporotic hip fracture in elderly residents of Utah. J Bone Miner Res 2004, 19(4):537-545.
-
(2004)
J Bone Miner Res
, vol.19
, Issue.4
, pp. 537-545
-
-
Wengreen, H.J.1
Munger, R.G.2
West, N.A.3
-
10
-
-
0033696402
-
Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study
-
Hannan M.T., Tucker K.L., Dawson-Hughes B., et al. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000, 15(12):2504-2512.
-
(2000)
J Bone Miner Res
, vol.15
, Issue.12
, pp. 2504-2512
-
-
Hannan, M.T.1
Tucker, K.L.2
Dawson-Hughes, B.3
-
11
-
-
0031661031
-
Dietary protein affects intestinal calcium absorption
-
Kerstetter J.E., O'Brien K.O., Insogna K.L. Dietary protein affects intestinal calcium absorption. Am J Clin Nutr 1998, 68(4):859-865.
-
(1998)
Am J Clin Nutr
, vol.68
, Issue.4
, pp. 859-865
-
-
Kerstetter, J.E.1
O'Brien, K.O.2
Insogna, K.L.3
-
12
-
-
0031817494
-
Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group
-
Gregg E.W., Cauley J.A., Seeley D.G., et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998, 129(2):81-88.
-
(1998)
Ann Intern Med
, vol.129
, Issue.2
, pp. 81-88
-
-
Gregg, E.W.1
Cauley, J.A.2
Seeley, D.G.3
-
13
-
-
0036048481
-
Exercise for preventing and treating osteoporosis in postmenopausal women
-
CD000333
-
Bonaiuti D., Shea B., Iovine R., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002, (3). CD000333.
-
(2002)
Cochrane Database Syst Rev
, Issue.3
-
-
Bonaiuti, D.1
Shea, B.2
Iovine, R.3
-
14
-
-
0029884643
-
Bisphosphonates: mechanisms of action
-
Rodan G.A., Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 1996, 97(12):2692-2696.
-
(1996)
J Clin Invest
, vol.97
, Issue.12
, pp. 2692-2696
-
-
Rodan, G.A.1
Fleisch, H.A.2
-
15
-
-
0029133135
-
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
-
Hughes D.E., Wright K.R., Uy H.L., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10(10):1478-1487.
-
(1995)
J Bone Miner Res
, vol.10
, Issue.10
, pp. 1478-1487
-
-
Hughes, D.E.1
Wright, K.R.2
Uy, H.L.3
-
16
-
-
33947109369
-
Bisphosphonates: mode of action and pharmacology
-
Russell R.G. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007, 119(Suppl 2):S150-S162.
-
(2007)
Pediatrics
, vol.119
, Issue.SUPPL 2
, pp. S150-S162
-
-
Russell, R.G.1
-
17
-
-
51349163043
-
Bisphosphonates: mechanism of action and role in clinical practice
-
Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008, 83(9):1032-1045.
-
(2008)
Mayo Clin Proc
, vol.83
, Issue.9
, pp. 1032-1045
-
-
Drake, M.T.1
Clarke, B.L.2
Khosla, S.3
-
18
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group
-
Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348(9041):1535-1541.
-
(1996)
Lancet
, vol.348
, Issue.9041
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
19
-
-
0032583492
-
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
-
Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280(24):2077-2082.
-
(1998)
JAMA
, vol.280
, Issue.24
, pp. 2077-2082
-
-
Cummings, S.R.1
Black, D.M.2
Thompson, D.E.3
-
20
-
-
0033552255
-
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group
-
Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282(14):1344-1352.
-
(1999)
JAMA
, vol.282
, Issue.14
, pp. 1344-1352
-
-
Harris, S.T.1
Watts, N.B.2
Genant, H.K.3
-
21
-
-
0035253489
-
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
-
McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001, 344(5):333-340.
-
(2001)
N Engl J Med
, vol.344
, Issue.5
, pp. 333-340
-
-
McClung, M.R.1
Geusens, P.2
Miller, P.D.3
-
22
-
-
4544262219
-
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
-
Chesnut I.C., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004, 19(8):1241-1249.
-
(2004)
J Bone Miner Res
, vol.19
, Issue.8
, pp. 1241-1249
-
-
Chesnut, I.C.1
Skag, A.2
Christiansen, C.3
-
23
-
-
34247866550
-
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
-
Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356(18):1809-1822.
-
(2007)
N Engl J Med
, vol.356
, Issue.18
, pp. 1809-1822
-
-
Black, D.M.1
Delmas, P.D.2
Eastell, R.3
-
24
-
-
84878164987
-
Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis
-
Gedmintas L., Solomon D.H., Kim S.C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013, 28(8):1729-1737.
-
(2013)
J Bone Miner Res
, vol.28
, Issue.8
, pp. 1729-1737
-
-
Gedmintas, L.1
Solomon, D.H.2
Kim, S.C.3
-
25
-
-
34848841461
-
Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research
-
Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
-
(2007)
J Bone Miner Res
, vol.22
, Issue.10
, pp. 1479-1491
-
-
Khosla, S.1
Burr, D.2
Cauley, J.3
-
26
-
-
33845890326
-
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial
-
Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006, 296(24):2927-2938.
-
(2006)
JAMA
, vol.296
, Issue.24
, pp. 2927-2938
-
-
Black, D.M.1
Schwartz, A.V.2
Ensrud, K.E.3
-
27
-
-
84861668653
-
Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?
-
Black D.M., Bauer D.C., Schwartz A.V., et al. Continuing bisphosphonate treatment for osteoporosis-for whom and for how long?. N Engl J Med 2012, 366(22):2051-2053.
-
(2012)
N Engl J Med
, vol.366
, Issue.22
, pp. 2051-2053
-
-
Black, D.M.1
Bauer, D.C.2
Schwartz, A.V.3
-
28
-
-
84856184102
-
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
-
Black D.M., Reid I.R., Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27(2):243-254.
-
(2012)
J Bone Miner Res
, vol.27
, Issue.2
, pp. 243-254
-
-
Black, D.M.1
Reid, I.R.2
Boonen, S.3
-
29
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
-
Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
-
(2002)
JAMA
, vol.288
, Issue.3
, pp. 321-333
-
-
Rossouw, J.E.1
Anderson, G.L.2
Prentice, R.L.3
-
30
-
-
0033581212
-
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators
-
Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999, 282(7):637-645.
-
(1999)
JAMA
, vol.282
, Issue.7
, pp. 637-645
-
-
Ettinger, B.1
Black, D.M.2
Mitlak, B.H.3
-
31
-
-
0035837553
-
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
-
Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344(19):1434-1441.
-
(2001)
N Engl J Med
, vol.344
, Issue.19
, pp. 1434-1441
-
-
Neer, R.M.1
Arnaud, C.D.2
Zanchetta, J.R.3
-
32
-
-
69049083492
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
-
Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
-
(2009)
N Engl J Med
, vol.361
, Issue.8
, pp. 756-765
-
-
Cummings, S.R.1
San Martin, J.2
McClung, M.R.3
-
33
-
-
84872332488
-
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
-
McClung M.R., Lewiecki E.M., Geller M.L., et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int 2013, 24(1):227-235.
-
(2013)
Osteoporos Int
, vol.24
, Issue.1
, pp. 227-235
-
-
McClung, M.R.1
Lewiecki, E.M.2
Geller, M.L.3
-
34
-
-
0033829969
-
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group
-
Chesnut C.H., Silverman S., Andriano K., et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109(4):267-276.
-
(2000)
Am J Med
, vol.109
, Issue.4
, pp. 267-276
-
-
Chesnut, C.H.1
Silverman, S.2
Andriano, K.3
-
35
-
-
0026671983
-
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study
-
Overgaard K., Hansen M.A., Jensen S.B., et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992, 305(6853):556-561.
-
(1992)
BMJ
, vol.305
, Issue.6853
, pp. 556-561
-
-
Overgaard, K.1
Hansen, M.A.2
Jensen, S.B.3
-
36
-
-
0023794243
-
Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment
-
Civitelli R., Gonnelli S., Zacchei F., et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 1988, 82(4):1268-1274.
-
(1988)
J Clin Invest
, vol.82
, Issue.4
, pp. 1268-1274
-
-
Civitelli, R.1
Gonnelli, S.2
Zacchei, F.3
|